{
    "clinical_study": {
        "@rank": "31704", 
        "arm_group": [
            {
                "arm_group_label": "Eperisone 50mg BID", 
                "arm_group_type": "Experimental", 
                "description": "Administrate Eperisone 50mg tablet after the breakfast and dinner, and pacebo tablet after the lunch for 7 days"
            }, 
            {
                "arm_group_label": "Epirisone 50mg TID", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo comparator", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Multi-center Study to Compare Efficacy and Safety between Eperisone a BID and a TID Regimen\n      in Acute Low Back Pain Patients during 7 days."
        }, 
        "brief_title": "Comparing Efficacy and Safety Between Eperisone a BID and a TID Regimen in Acute Low Back Pain Patients", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Low Back Pain", 
        "condition_browse": {
            "mesh_term": [
                "Back Pain", 
                "Low Back Pain"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who have ability to comprehend the contents of study and before\n             participating in trial and have willingness to sign of informed consent in writing\n\n          -  20\u2264 age \u226460\n\n          -  A patient has symptom of acute low back pain\n\n          -  4\u2264 VAS\n\n        Exclusion Criteria:\n\n          -  Subjects who cannot prohibit anti-inflammatory drug, painkiller or muscle relaxants\n             during clinical trial\n\n          -  Chronic rheumatoid arthritis patients\n\n          -  Patients having a medical history of hypersensitivity to Eperisone Hydrochloride\n\n          -  Subject having a hereditary problem such as galactose intolerance, Lapp lactase\n             deficiency, or glucose galatose malabsorption\n\n          -  Participation in other studies before 60 days of first dosing\n\n          -  Female patients having positive pregnancy test, lactating women,planning pregnancy\n             during clinical trial\n\n          -  Inadequate subject for the clinical trial by the investigator's decision"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "98", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806818", 
            "org_study_id": "HM-EPAC-201"
        }, 
        "intervention": {
            "arm_group_label": [
                "Eperisone 50mg BID", 
                "Epirisone 50mg TID", 
                "Placebo comparator"
            ], 
            "description": "3 times a day after meals for 1 week", 
            "intervention_name": "Epirisone 50mg or placebo TID", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Eperisone"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 22, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anyang", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Hallym University Sacred Heart Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Medical college of Yonsei University, Gangnam Severance Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Severance Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Kyung Hee University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "CHA Bundang Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2, Randomized, Double-blind, Parallel, Placebo-controlled, Multi-center Study to Compare Efficacy and Safety Between Eperisone a BID and a TID Regimen in Acute Low Back Pain Patients", 
        "overall_official": {
            "affiliation": "Gangnam Severance Hospital", 
            "last_name": "Hak-Sun Kim, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "VAS improvement of pain at rest, on movement and at night", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806818"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change of Modified Schober test", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Change of Lateral Body Bending test", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Change of EuroQol by patients", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Change of Oswestry Disability Index", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Overall pain improvement by investigator", 
                "safety_issue": "No", 
                "time_frame": "at last visit (D7+2)"
            }
        ], 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}